Eun-Sun Choi1, Sejun Oh2, Boonsil Jang2, Hyun-Ju Yu2, Ji-Ae Shin3, Nam-Pyo Cho2, In-Hyoung Yang2, Dong-Hoon Won3, Hye-Jeong Kwon3, Seong Doo Hong3, Sung-Dae Cho4. 1. Division of high-risk pathogen research, Korea Centers for Disease Control and Prevention, Osong, 28160, Republic of Korea. 2. Department of Oral Pathology, School of Dentistry and Institute of Biodegradable material, Institute of Oral Bioscience, Chonbuk National University, Brain Korea 21 Project, Jeonju, 54986, Republic of Korea. 3. Department of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, 03080, Republic of Korea. 4. Department of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, 03080, Republic of Korea. efiwdsc@snu.ac.kr.
Abstract
PURPOSE: Approximately 20% of all salivary gland cancer patients who are treated with current treatment modalities will ultimately develop metastases. Its most common form, mucoepidermoid carcinoma (MEC) is a highly aggressive tumor with an overall 5-year survival rate of ~30%. Until now, several chemotherapeutic drugs have been tested for the treatment of salivary gland tumors, but the results have been disappointing and the drugs often cause unwanted side effects. Therefore, several recent studies have focused on the potential of alternative and/or complementary therapeutic options, including the use of silymarin. METHODS: The effects of silymarin and its active component silibinin on salivary gland cancer-derived MC3 and HN22 cells and their underlying molecular mechanisms were examined using trypan blue exclusion, 4'-6-diamidino-2-phenylindole (DAPI) staining, Live/Dead, Annexin V/PI staining, mitochondrial membrane potential (ΔΨm) measurement, quantitative RT-PCR, soft agar colony formation and Western blotting analyses. RESULTS: We found that silymarin and silibinin dramatically increased the expression of the pro-apoptotic protein Bim in a concentration- and time-dependent manner and, concomitantly, induced apoptosis in MC3 and HN22 cells. We also found that ERK1/2 signaling inhibition successfully sensitized these cells to the apoptotic effects of silymarin and silibinin, which indicates that the ERK1/2 signaling pathway may act as an upstream regulator that modulates the silymarin/silibinin-induced Bim signaling pathway. CONCLUSIONS: Taken together, we conclude that ERK1/2 signaling pathway inhibition by silymarin and silibinin increases the expression of the pro-apoptotic Bcl-2 family member Bim which, subsequently, induces mitochondria-mediated apoptosis in salivary gland cancer-derived cells.
PURPOSE: Approximately 20% of all salivary gland cancerpatients who are treated with current treatment modalities will ultimately develop metastases. Its most common form, mucoepidermoid carcinoma (MEC) is a highly aggressive tumor with an overall 5-year survival rate of ~30%. Until now, several chemotherapeutic drugs have been tested for the treatment of salivary gland tumors, but the results have been disappointing and the drugs often cause unwanted side effects. Therefore, several recent studies have focused on the potential of alternative and/or complementary therapeutic options, including the use of silymarin. METHODS: The effects of silymarin and its active component silibinin on salivary gland cancer-derived MC3 and HN22 cells and their underlying molecular mechanisms were examined using trypan blue exclusion, 4'-6-diamidino-2-phenylindole (DAPI) staining, Live/Dead, Annexin V/PI staining, mitochondrial membrane potential (ΔΨm) measurement, quantitative RT-PCR, soft agar colony formation and Western blotting analyses. RESULTS: We found that silymarin and silibinin dramatically increased the expression of the pro-apoptotic protein Bim in a concentration- and time-dependent manner and, concomitantly, induced apoptosis in MC3 and HN22 cells. We also found that ERK1/2 signaling inhibition successfully sensitized these cells to the apoptotic effects of silymarin and silibinin, which indicates that the ERK1/2 signaling pathway may act as an upstream regulator that modulates the silymarin/silibinin-induced Bim signaling pathway. CONCLUSIONS: Taken together, we conclude that ERK1/2 signaling pathway inhibition by silymarin and silibinin increases the expression of the pro-apoptotic Bcl-2 family member Bim which, subsequently, induces mitochondria-mediated apoptosis in salivary gland cancer-derived cells.
Authors: Stephan Schwarz; Clemens Stiegler; Maximilian Müller; Tobias Ettl; Gero Brockhoff; Johannes Zenk; Abbas Agaimy Journal: Histopathology Date: 2011-03-03 Impact factor: 5.087
Authors: G Scambia; R De Vincenzo; F O Ranelletti; P B Panici; G Ferrandina; G D'Agostino; A Fattorossi; E Bombardelli; S Mancuso Journal: Eur J Cancer Date: 1996-05 Impact factor: 9.162
Authors: Renata L Markman; Liana P Webber; Carlos H V Nascimento Filho; Leonardo A Reis; Pablo A Vargas; Marcio A Lopes; Virgilio Zanella; Manoela D Martins; Cristiane H Squarize; Rogerio M Castilho Journal: Cell Oncol (Dordr) Date: 2018-12-11 Impact factor: 6.730
Authors: Jan-Henrik Mikesch; Wolfgang Hartmann; Linus Angenendt; Otmar Huber; Christoph Schliemann; Maria Francisca Arteaga; Eva Wardelmann; Claudia Rudack; Wolfgang E Berdel; Markus Stenner; Inga Grünewald Journal: Cell Oncol (Dordr) Date: 2018-06-05 Impact factor: 6.730